Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

Similar articles for PubMed (Select 19173737)

1.

Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.

Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D.

BMC Cancer. 2009 Jan 27;9:34. doi: 10.1186/1471-2407-9-34. Review.

2.

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.

Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS.

Eur Urol. 2015 May 4. pii: S0302-2838(15)00319-X. doi: 10.1016/j.eururo.2015.04.017. [Epub ahead of print]

4.

Therapeutic effects and associated adverse events of first-line treatments of advanced renal cell carcinoma (RCC): a meta-analysis.

Wang L, Ma L, Wang X, Li B, Guo S, Qiao Q.

Int Urol Nephrol. 2015 Apr;47(4):617-24. doi: 10.1007/s11255-015-0932-1. Epub 2015 Feb 17.

PMID:
25686740
5.

89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.

Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, Hollema H, de Jong JR, de Jong IJ, de Haas S, Scherer SJ, Sluiter WJ, Dierckx RA, Bongaerts AH, Gietema JA, de Vries EG.

J Nucl Med. 2015 Jan;56(1):63-9. doi: 10.2967/jnumed.114.144840. Epub 2014 Dec 4.

PMID:
25476536
6.

Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis.

Nearchou A, Valachis A, Lind P, Akre O, Sandström P.

Clin Genitourin Cancer. 2014 Oct 24. pii: S1558-7673(14)00232-8. doi: 10.1016/j.clgc.2014.10.002. [Epub ahead of print] Review.

PMID:
25442773
7.

Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data.

Iacovelli R, Santoni M, Verzoni E, Grassi P, Testa I, de Braud F, Cascinu S, Procopio G.

Clin Genitourin Cancer. 2015 Apr;13(2):137-41. doi: 10.1016/j.clgc.2014.07.006. Epub 2014 Aug 2.

PMID:
25160521
10.

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.

Négrier S, Bushmakin AG, Cappelleri JC, Korytowsky B, Sandin R, Charbonneau C, Michaelson MD, Figlin RA, Motzer RJ.

Eur J Cancer. 2014 Jul;50(10):1766-71. doi: 10.1016/j.ejca.2014.03.012. Epub 2014 Apr 23.

11.

Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma.

Thiery-Vuillemin A, Mouillet G, Nguyen Tan Hon T, Montcuquet P, Maurina T, Almotlak H, Stein U, Montange D, Foubert A, Nerich V, Pivot X, Royer B.

Cancer Chemother Pharmacol. 2014 May;73(5):999-1007. doi: 10.1007/s00280-014-2435-7. Epub 2014 Mar 30.

PMID:
24682543
12.

Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.

Clark O, Botrel TE, Paladini L, Ferreira MB.

Core Evid. 2014 Jan 6;9:1-11. doi: 10.2147/CE.S52197. eCollection 2014. Review.

13.

Systematic review and meta-analysis of target terapies for the treatment of metastatic renal cancer.

Durán M, Matheus W, Ferreira U, Clark O.

Int Braz J Urol. 2013 Nov-Dec;39(6):768-78. doi: 10.1590/S1677-5538.IBJU.2013.06.02. Review.

14.

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.

Halabi S, Rini B, Escudier B, Stadler WM, Small EJ.

Cancer. 2014 Jan 1;120(1):52-60. doi: 10.1002/cncr.28221. Epub 2013 Oct 8.

15.

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.

Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ.

Curr Med Res Opin. 2014 Apr;30(4):537-45. doi: 10.1185/03007995.2013.871243. Epub 2013 Dec 17.

PMID:
24329572
16.

A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.

P J G, A M, L M, H J H, M K, S B, N M.

Urol Oncol. 2014 Apr;32(3):362-70. doi: 10.1016/j.urolonc.2013.09.009. Epub 2013 Dec 8.

PMID:
24321255
17.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ.

J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961. Epub 2013 Dec 2.

18.

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B.

J Clin Oncol. 2014 Mar 10;32(8):752-9. doi: 10.1200/JCO.2013.50.5305. Epub 2013 Dec 2.

19.

Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.

Mihajlović J, Pechlivanoglou P, Sabo A, Tomić Z, Postma MJ.

Clin Ther. 2013 Dec;35(12):1909-22. doi: 10.1016/j.clinthera.2013.10.004. Epub 2013 Nov 13.

PMID:
24238790
20.

Advanced kidney cancer: treating the elderly.

Zustovich F, Novara G.

Expert Rev Anticancer Ther. 2013 Dec;13(12):1389-98. doi: 10.1586/14737140.2013.846095. Epub 2013 Nov 14. Review.

PMID:
24224483
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk